Bildkälla: Stockfoto

InDex Pharmaceuticals: Q3 2022, glimpsing an exciting 2023 - Redeye

Redeye leaves its comments on InDex Pharmaceuticals following its Q3 2022 report. The report did not contain any significant surprises, and the trajectory of the ongoing phase lll-trial CONCLUDE remains the most vital thing for the company.

Redeye leaves its comments on InDex Pharmaceuticals following its Q3 2022 report. The report did not contain any significant surprises, and the trajectory of the ongoing phase lll-trial CONCLUDE remains the most vital thing for the company.
Börsvärldens nyhetsbrev
ANNONSER